Wellorithm vs Enhance.MD: put each price in the right month

Put the three displayed prices on a timeline

Wellorithm and Enhance.MD put three numbers on two different timelines. Wellorithm publishes a $147 starting price, but the reviewed evidence does not establish what later months cost. Enhance.MD publishes a first month from $112 and also a $212 monthly figure. The first task is to label each amount by the period it covers, not to rank the smallest number.

For Wellorithm, request the first charge, month-two amount, later recurring amount, and every condition that can change the price. For Enhance.MD, ask what the first month from $112 includes, when the $212 monthly statement begins to apply, and whether medication, consultation, supplies, and shipping sit inside either figure. A timeline prevents an introductory amount from being compared with a recurring amount.

Do not fill Wellorithm’s later months with the $147 starting figure. The reviewed evidence does not support that assumption. It also does not support the opposite assumption that later months must be higher. "Unknown" is a bounded finding about the cited page, not a judgment about value or quality.

Align the billing periods before calculating totals

Build totals only after the periods align. Compare amount due now, recurring amount, and the full minimum obligation. If the two quotes involve different product forms, service bundles, or commitments, show separate scenarios rather than one winner.

Keep the page date beside every number. A later visit may show different pricing or terms, and an older captured figure does not become false merely because it changes. It does become unsuitable as a current quote. Reopen the official page and checkout when the decision is made, then preserve the current wording with the calculation.

Use separate rows for first-month discount, ordinary recurring amount, minimum duration, and price-change conditions. That layout makes a missing recurring field obvious. It also prevents the $112 first-month figure, the $147 starting figure, and the $212 monthly statement from being treated as though each described the same product and period.

What the Enhance.MD recurring figure clarifies

Enhance.MD makes one common price transition more visible by publishing both a first-month starting figure and a $212 monthly statement. That is useful evidence because it warns against carrying the introductory amount forward. It does not answer every billing question. The exact checkout amount, dose-related changes, commitment, laboratory work, and included services still require confirmation.

Ask which event moves the account from the first-month amount to the recurring figure. Also ask when each charge occurs, whether the product or dose can change the amount, and whether cancellation before a later charge is possible under the current terms. Save the response with the checkout summary rather than relying on the smallest number in a page header.

Wellorithm’s page provides a $147 starting point but not the same step-by-step price evidence in the reviewed extract. That makes the recurring field less complete, not automatically less favorable. A comparison should reward clarity without inventing a total for the less complete side.

The amount due at enrollment matters alongside the monthly labels. Ask whether the first charge covers one period or a longer supply cadence, whether a later charge is scheduled automatically, and which written cancellation term applies before that charge. The reviewed evidence does not answer those questions for every transaction, so the checklist should leave them open until the companies do.

Product wording and FDA status are separate

Wellorithm says FDA has not reviewed the medications for safety, quality, or effectiveness. Enhance.MD states that the medication is compounded and not FDA-approved. These statements preserve the regulatory distinction for the product pathways described on the pages.

FDA states that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality. A familiar ingredient, professional-supervision statement, pharmacy reference, or delivery schedule does not convert a compounded preparation into an FDA-approved branded drug.

Before payment, ask for the exact formulation, prescriber, dispensing pharmacy, and current availability. This commercial comparison does not claim equivalence between product categories and does not advise which drug, formulation, or dose anyone should use.

What the pages say about professional review

Wellorithm states that prescription drugs must be used under a licensed healthcare professional’s supervision. Enhance.MD says prescription products require an online consultation and describes ongoing provider care and support. Those statements show that both pages describe professional involvement, but they do not prove that a particular person qualifies or that a prescription will be written.

Turn broad oversight language into practical questions. Who reviews the intake? When does the review occur? Are follow-up contacts included in the displayed amount? Which channel handles routine questions? Does another fee apply when more review is needed? Written scope is more useful than a general care label when comparing the bill.

The evidence also does not support a clinical-quality ranking. More detailed marketing language can make a process easier to understand without proving better medical outcomes. Individual eligibility, risks, symptoms, and treatment changes belong with a qualified healthcare professional.

Ask whether the person answering routine billing questions is the same contact who handles care questions, and whether ongoing support begins before or after a prescription decision. The reviewed statements do not establish those details. Keeping administrative and clinical channels separate makes the service scope easier to compare without implying that either program offers superior care.

A delivery cadence is not a delivery window

Wellorithm states free direct-to-door shipping, but the reviewed extract does not state dispatch or delivery timing. Enhance.MD says medication is shipped to the door and references a 12-week cadence, not an elapsed delivery window. Cadence describes recurrence. A delivery window describes how long a particular shipment takes.

Ask when the pharmacy receives the prescription, what starts the processing clock, when the carrier takes possession, whether tracking is provided, and who handles delay or damage. Do not infer an intake-to-door estimate from either page. Free shipping answers the fee field only.

Keep product-specific handling questions with the dispensing pharmacy and clinician. A comparison can ask whether instructions and an exception route exist, but it should not invent storage rules or tell a reader what to do with a product that arrives late or damaged.

HSA and FSA acceptance is not reimbursement

Wellorithm describes HSA/FSA use and says insurance is not required. Enhance.MD also describes HSA/FSA use, while the reviewed extract does not establish insurance coverage. These are payment statements. They do not guarantee that a plan administrator will approve the exact charge.

Request an itemized receipt that names the billed entity and separates medication, consultation, membership, supplies, and shipping. Then ask the applicable administrator about those actual components. Merchant acceptance, account eligibility, reimbursement, and insurance coverage should remain separate rows in the checklist.

If reimbursement would materially affect affordability, compare the cash price without assuming it. This preserves the commercial facts without turning a checkout method into a coverage promise or tax conclusion.

Resolve the unknowns before comparing totals

Use one checklist for both companies: exact product, first charge, recurring charge, minimum duration, included clinician care, separate fees, shipping cost and timing, renewal, cancellation, refund boundary, payment methods, and source date. Mark each field confirmed, variable, or not stated.

For Wellorithm, the decisive missing field is the later-month total in the reviewed evidence. For Enhance.MD, the published transition is clearer, but the exact conditions and included items still matter. Recheck both official pages immediately before a decision because prices, availability, pharmacy relationships, and terms can change.

The narrow conclusion is about evidence, not treatment. Enhance.MD provides more visibility into an introductory-to-recurring price change. Wellorithm provides a $147 starting point whose later-month amount remains unresolved. Neither fact supports a medical recommendation or a universal best-provider label.

Save the final comparison in plain language: what each company would charge first, what it would charge later, how long the commitment lasts, what the price includes, and which entries remain unknown. If one unresolved field could reverse the choice, the comparison is not finished. That is a stronger consumer conclusion than awarding a winner to the smallest displayed number.

Reconcile the first invoice against the saved quote. A charge may match, vary under a disclosed rule, or require explanation. Keep any written clarification with the original terms. That record is specific to the transaction and should not be turned into a claim that every customer will receive the same price or experience. Reopen the comparison if the formulation, payment schedule, or renewal terms change.